A detailed history of Tower Research Capital LLC (Trc) transactions in Clene Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 9,832 shares of CLNN stock, worth $3,244. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,832
Previous 26,117 62.35%
Holding current value
$3,244
Previous $7,000 42.86%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.28 - $0.53 $4,559 - $8,631
-16,285 Reduced 62.35%
9,832 $4,000
Q4 2023

Feb 13, 2024

SELL
$0.26 - $0.55 $193 - $410
-746 Reduced 2.78%
26,117 $7,000
Q3 2023

Nov 14, 2023

BUY
$0.46 - $0.87 $5,528 - $10,456
12,019 Added 80.97%
26,863 $13,000
Q2 2023

Aug 14, 2023

BUY
$0.78 - $1.22 $3,429 - $5,364
4,397 Added 42.09%
14,844 $13,000
Q1 2023

May 09, 2023

BUY
$0.95 - $1.62 $1,055 - $1,799
1,111 Added 11.9%
10,447 $12,000
Q4 2022

Feb 10, 2023

SELL
$0.92 - $1.11 $4,638 - $5,596
-5,042 Reduced 35.07%
9,336 $9,000
Q3 2022

Nov 10, 2022

BUY
$0.33 - $4.83 $3,348 - $49,010
10,147 Added 239.83%
14,378 $40,000
Q2 2022

Aug 15, 2022

BUY
$2.1 - $4.12 $2,803 - $5,500
1,335 Added 46.1%
4,231 $11,000
Q1 2022

May 12, 2022

SELL
$2.42 - $4.42 $6,821 - $12,459
-2,819 Reduced 49.33%
2,896 $11,000
Q4 2021

Feb 14, 2022

BUY
$3.95 - $7.53 $12,011 - $22,898
3,041 Added 113.72%
5,715 $23,000
Q3 2021

Nov 15, 2021

BUY
$6.83 - $13.58 $17,102 - $34,004
2,504 Added 1472.94%
2,674 $18,000
Q2 2021

Aug 16, 2021

SELL
$6.98 - $13.33 $300 - $573
-43 Reduced 20.19%
170 $2,000
Q1 2021

May 17, 2021

BUY
$6.39 - $16.3 $1,361 - $3,471
213 New
213 $3,000

Others Institutions Holding CLNN

About Clene Inc.


  • Ticker CLNN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,502,000
  • Market Cap $21M
  • Description
  • Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...
More about CLNN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.